Nuvation Bio (NUVB) Total Liabilities (2020 - 2026)

Nuvation Bio (NUVB) has reported Total Liabilities for 7 consecutive years, with $290.7 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Total Liabilities rose 298.03% year-over-year to $290.7 million; the TTM figure through Mar 2026 stood at $290.7 million (up 298.03% YoY), while the FY2025 annual figure was $289.1 million, up 276.25% from the prior year.
• Total Liabilities grew to $290.7 million in Q1 2026 per NUVB's latest filing, from $289.1 million in the prior quarter.
• Across five years, Total Liabilities topped out at $290.7 million in Q1 2026 and bottomed at $16.0 million in Q1 2023.
• Historically, Total Liabilities has averaged $93.5 million across 5 years, with a median of $28.2 million in 2022.
• Annual changes were most pronounced in 2022 — Total Liabilities plunged 43.41% — and 2024, when it surged 369.61%.
• Nuvation Bio's Total Liabilities stood at $17.1 million in 2022, then dropped by 4.12% to $16.4 million in 2023, then soared by 369.61% to $76.8 million in 2024, then jumped by 276.25% to $289.1 million in 2025, then climbed by 0.54% to $290.7 million in 2026.
• Business Quant data shows NUVB's Total Liabilities at $290.7 million in Q1 2026, $289.1 million in Q4 2025, and $275.7 million in Q3 2025.